SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Recent advances in diagnostic and therapeutic approaches for pulmonary enteric adenocarcinoma.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pulmonary enteric adenocarcinoma (PEAC), also known as adenocarcinoma-enteric type of the lung, is a rare variant of non-small cell lung cancer (NSCLC) that shows similar morphological and immunohistochemical (IHC) features to colorectal adenocarcinoma and necessitates gastroenteroscopy to exclude enteric-origin lesions. Moreover, IHC diagnostic criteria for PEAC are more explicitly defined in the 2015 World Health Organization (WHO) Classification of Lung Tumors. When the percentage of tumor cells with enteric differentiation exceeds > 50% of tumor tissue, then at least one enteric differentiation marker [cytokeratin 20 (CK20), tail homologous box (CDX2), mucin 2 (MUC2), and specific AT-sequence binding protein 2 (SATB2)] is detected. This PEAC, an uncommon solid tumor in lung cancer, is characterized by a poor prognosis, pathological and molecular traits, and a unique clinical response in imaging. However, their molecular features and therapeutic biomarkers are still unexplored, and their diagnosis and treatment remain difficult. Thus, systematic review and combined analysis data were obtained from previously published literature.
Indexed as
Identifiers
41402694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.